DE602004029393D1 - Tgf-beta1-bindende und geträgerte peptide - Google Patents

Tgf-beta1-bindende und geträgerte peptide

Info

Publication number
DE602004029393D1
DE602004029393D1 DE602004029393T DE602004029393T DE602004029393D1 DE 602004029393 D1 DE602004029393 D1 DE 602004029393D1 DE 602004029393 T DE602004029393 T DE 602004029393T DE 602004029393 T DE602004029393 T DE 602004029393T DE 602004029393 D1 DE602004029393 D1 DE 602004029393D1
Authority
DE
Germany
Prior art keywords
peptides
supported
tgf
preferred embodiments
supported peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004029393T
Other languages
English (en)
Inventor
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Beverly R Turnquest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco US Inc filed Critical Danisco US Inc
Publication of DE602004029393D1 publication Critical patent/DE602004029393D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
DE602004029393T 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide Active DE602004029393D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53095403P 2003-12-19 2003-12-19
US53120703P 2003-12-19 2003-12-19
US53118903P 2003-12-19 2003-12-19
PCT/US2004/036979 WO2005046710A2 (en) 2003-11-06 2004-11-06 Tgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
DE602004029393D1 true DE602004029393D1 (de) 2010-11-11

Family

ID=34596198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004029393T Active DE602004029393D1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide
DE602004029812T Active DE602004029812D1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004029812T Active DE602004029812D1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1692158B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE513917T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029393D1 (de)
DK (2) DK1680507T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005047314A2 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292641B1 (de) * 2003-11-06 2017-12-06 Danisco US Inc. Expression in faserigen Pilzen von Proteasehemmern und Varianten davon
DE602004029393D1 (de) * 2003-11-06 2010-11-11 Danisco Us Inc Tgf-beta1-bindende und geträgerte peptide
WO2006044650A2 (en) * 2004-10-15 2006-04-27 Genencor International, Inc. Competitive differential screening
US9084734B2 (en) * 2005-05-05 2015-07-21 Danisco Us Inc. Peptide personal care compositions and methods for their use
DK1904529T3 (da) * 2005-06-10 2010-11-15 Medical Res Council Anvendelse af Stefin A som et scaffoldprotein
KR20080042070A (ko) * 2005-07-13 2008-05-14 암젠 마운틴 뷰 인코포레이티드 Ｉｌ-6 결합 단백질
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
PT2061313E (pt) * 2006-09-16 2013-09-23 Soy Labs Llc Produtos e métodos que usam péptidos de soja para reduzir os níveis de colesterol total e de colesterol ldl
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
EP2094842B1 (de) * 2006-12-18 2012-06-13 Danisco US Inc. Neue laccasen, zusammensetzungen und verwendungsverfahren dafür
WO2008088493A2 (en) 2006-12-21 2008-07-24 Danisco Us, Inc., Genencor Division Compositions and uses for an alpha-amylase polypeptide of bacillus species 195
CA2690055A1 (en) * 2007-06-06 2008-12-18 Danisco Us Inc. Methods for improving protein performance
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
RU2010121829A (ru) * 2007-10-31 2011-12-10 ДАНИСКО ЮЭс ИНК. (US) Применение и получение нейтральных металлопротеаз на фоне, свободном от сериновых протеаз
US20090221030A1 (en) * 2007-11-01 2009-09-03 Kai Bao Signal sequences and co-expressed chaperones for improving protein production in a host cell
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
WO2009096916A1 (en) * 2008-01-29 2009-08-06 Genencor International, Inc. Expression of streptomyces subtilisin inhibitor (ssi) proteins in bacillus and streptomyces sp.
AU2009212526A1 (en) 2008-02-04 2009-08-13 Danisco Us Inc. TS23 alpha-amylase variants with altered properties
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
CN102245635B (zh) * 2008-10-15 2016-08-31 丹尼斯科美国公司 修饰的变体bowman birk蛋白酶抑制剂
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20120172275A1 (en) 2009-03-10 2012-07-05 Danisco Us Inc. Bacillus Megaterium Strain DSM90-Related Alpha-Amylases, and Methods of Use, Thereof
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
EP2417254B1 (de) 2009-04-08 2014-05-21 Danisco US Inc. Alpha-amylasen in verbindung mit halomonas-stamm wdg195 sowie verfahren zur verwendung davon
US8530218B2 (en) * 2009-04-24 2013-09-10 Danisco Us Inc. Proteases with modified pro regions
MX2011011619A (es) * 2009-05-01 2012-02-28 Signal Invest And Man Co Composicion antimicrobiana hidratante.
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
EP2478003A4 (de) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc Haarwuchsverfahren unter verwendung extrazellulärer fgfr4-domänen
GB0921001D0 (en) 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
US8728790B2 (en) 2009-12-09 2014-05-20 Danisco Us Inc. Compositions and methods comprising protease variants
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
CN102781459A (zh) * 2009-12-30 2012-11-14 索莱有限责任公司 从大豆工艺流中分离的纯化的鲍曼-贝克蛋白酶抑制剂蛋白
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
ES2574056T3 (es) * 2010-03-31 2016-06-14 Agency For Science, Technology And Research Péptido/peptoide anfifílico lineal e hidrogel que comprende el mismo
EP2558573B1 (de) 2010-04-15 2017-02-22 Danisco US Inc. Zusammensetzungen und verfahren mit proteasevarianten
HUE034524T2 (en) 2010-05-06 2018-02-28 Procter & Gamble Consumer articles with protease variants
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP3486319B1 (de) 2011-05-05 2022-11-30 Danisco US Inc. Zusammensetzungen und verfahren mit serinproteasevarianten
MX357386B (es) 2011-05-05 2018-07-06 Procter & Gamble Composiciones y metodos que comprenden variantes de proteasa serina.
CN103781903A (zh) 2011-08-31 2014-05-07 丹尼斯科美国公司 包含脂肪分解酶变体的组合物和方法
US20150017700A1 (en) 2011-12-22 2015-01-15 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
AU2013328953A1 (en) 2012-10-12 2015-03-26 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
CN104781400A (zh) 2012-11-05 2015-07-15 丹尼斯科美国公司 包含嗜热菌蛋白酶变体的组合物和方法
EP2935573A1 (de) 2012-12-19 2015-10-28 Danisco US Inc. Neuartige mannase, zusammensetzungen und verfahren zur verwendung davon
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3882346A1 (de) 2013-05-29 2021-09-22 Danisco US Inc. Neuartige metalloproteasen
US20160122738A1 (en) 2013-05-29 2016-05-05 Danisco Us Inc. Novel metalloproteases
US20160108387A1 (en) 2013-05-29 2016-04-21 Danisco Us Inc. Novel metalloproteases
EP3004314B1 (de) 2013-05-29 2018-06-20 Danisco US Inc. Neuartige metalloproteasen
MX2020001159A (es) 2013-07-19 2021-07-07 Danisco Us Inc Composiciones y metodos que comprenden una variante de enzima lipolitica.
US20160222368A1 (en) 2013-09-12 2016-08-04 Danisco Us Inc. Compositions and Methods Comprising LG12-CLADE Protease Variants
KR20160068855A (ko) * 2013-10-11 2016-06-15 제넨테크, 인크. Nsp4 억제제 및 사용 방법
CN105813695A (zh) 2013-11-01 2016-07-27 斯弗尤姆生物制药有限公司 用于透皮递送治疗剂和美容剂的包含体
DK3514230T3 (da) 2013-12-13 2021-11-15 Danisco Us Inc Serinproteaser af bacillus-arter
EP3080263B1 (de) 2013-12-13 2019-07-03 Danisco US Inc. Serinproteasen des bazillus gibsonii-clade
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
DK3119884T3 (da) 2014-03-21 2019-10-14 Danisco Us Inc Serinproteaser af bacillus-arter
WO2016061438A1 (en) 2014-10-17 2016-04-21 Danisco Us Inc. Serine proteases of bacillus species
EP3957729A1 (de) 2014-10-27 2022-02-23 Danisco US Inc. Serinproteasen
US20180010074A1 (en) 2014-10-27 2018-01-11 Danisco Us Inc. Serine proteases of bacillus species
DK3212781T3 (da) 2014-10-27 2019-12-16 Danisco Us Inc Serinproteaser
EP4403631A2 (de) 2014-10-27 2024-07-24 Danisco US Inc. Serinproteasen
DK3212662T3 (da) 2014-10-27 2020-07-20 Danisco Us Inc Serinproteaser
US20180216090A1 (en) 2015-03-12 2018-08-02 Danisco Us Inc. Compositions and methods comprising lg12-clade protease variants
WO2016183509A1 (en) 2015-05-13 2016-11-17 Danisco Us Inc. AprL-CLADE PROTEASE VARIANTS AND USES THEREOF
EP4234693A3 (de) 2015-06-17 2023-11-01 Danisco US Inc Bacillus-gibboni-clade-serin-proteasen
JP7134629B2 (ja) 2015-06-17 2022-09-12 ダニスコ・ユーエス・インク 改変プロペプチド領域を備えるプロテアーゼ
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
WO2017192300A1 (en) 2016-05-05 2017-11-09 Danisco Us Inc Protease variants and uses thereof
CN109477112A (zh) 2016-05-31 2019-03-15 丹尼斯科美国公司 蛋白酶变体及其用途
EP3472313B1 (de) 2016-06-17 2022-08-31 Danisco US Inc. Proteasevarianten und verwendungen davon
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3559226B1 (de) 2016-12-21 2023-01-04 Danisco US Inc. Bacillus-gibboni-clade-serin-proteasen
US20200392477A1 (en) 2016-12-21 2020-12-17 Danisco Us Inc. Protease variants and uses thereof
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
EP3717643A1 (de) 2017-11-29 2020-10-07 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
US20210363470A1 (en) 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
WO2020046613A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
CN112368388B (zh) * 2018-10-31 2024-01-02 青岛蔚蓝生物集团有限公司 一种生产具有蛋白酶抗性的洗涤用酶的方法
EP3887515A1 (de) 2018-11-28 2021-10-06 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
EP3976776A1 (de) 2019-05-24 2022-04-06 Danisco US Inc. Subtilisin-varianten und verwendungsverfahren
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
US20230049452A1 (en) 2020-01-13 2023-02-16 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
US20240034960A1 (en) 2020-08-27 2024-02-01 Danisco Us Inc Enzymes and enzyme compositions for cleaning
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
CN117916354A (zh) 2021-09-03 2024-04-19 丹尼斯科美国公司 用于清洁的衣物洗涤组合物
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
CN118369414A (zh) 2021-12-16 2024-07-19 宝洁公司 包含蛋白酶的自动盘碟洗涤组合物
CA3240638A1 (en) 2021-12-16 2023-06-22 Michelle Jackson Fabric and home care composition comprising a protease
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
WO2024102698A1 (en) 2022-11-09 2024-05-16 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3929678A (en) * 1974-08-01 1975-12-30 Procter & Gamble Detergent composition having enhanced particulate soil removal performance
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) * 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) * 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
AU709850B2 (en) 1994-11-28 1999-09-09 Procter & Gamble Company, The Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents
AU5713896A (en) * 1996-03-12 1997-10-01 Genencor International, Inc. Alkaline cellulase and method of producing same
EP0991422A1 (de) * 1996-04-18 2000-04-12 The General Hospital Corporation Modulierende interaktionen des epitheliums und des mesenchyms
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AU734338B2 (en) 1996-11-22 2001-06-14 Procter & Gamble Company, The Cosmetic compositions
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
EA003637B1 (ru) * 1998-07-20 2003-08-28 Инокселл А/С Новые способы идентификации биомолекул лигандов и мишеней
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
AU1275599A (en) 1998-10-23 2000-05-15 Procter & Gamble Company, The Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP4966470B2 (ja) * 2000-04-14 2012-07-04 ダニスコ・ユーエス・インコーポレーテッド 選択性標的化方法
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2002002621A2 (en) * 2000-06-30 2002-01-10 Zymogenetics, Inc. Mammalian secreted proteins
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
JP4493271B2 (ja) * 2000-12-13 2010-06-30 アナフォア インコーポレイテッド Ｃ型レクチン様ドメインの骨格構造を有する蛋白質のコンビナトリアルライブラリ
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
EP1379549A2 (de) * 2001-02-07 2004-01-14 Institut Pasteur Genomsequenz des photorhabdus luminescens stamms tt01 und verwendungen
WO2004072223A2 (en) * 2003-02-11 2004-08-26 Institut Pasteur Identification and characterization of racemases, definition of protein signatures, and a test for detecting d-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase
DE602004029393D1 (de) * 2003-11-06 2010-11-11 Danisco Us Inc Tgf-beta1-bindende und geträgerte peptide
EP2292641B1 (de) * 2003-11-06 2017-12-06 Danisco US Inc. Expression in faserigen Pilzen von Proteasehemmern und Varianten davon
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors

Also Published As

Publication number Publication date
WO2005046710A2 (en) 2005-05-26
US7413877B2 (en) 2008-08-19
WO2005047511A3 (en) 2005-11-24
WO2005047511A2 (en) 2005-05-26
US20080113917A1 (en) 2008-05-15
EP1692158A2 (de) 2006-08-23
EP1692159A2 (de) 2006-08-23
CA2544820C (en) 2014-02-18
ATE482972T1 (de) 2010-10-15
WO2005047314A3 (en) 2006-04-20
US20090111160A1 (en) 2009-04-30
US7696173B2 (en) 2010-04-13
WO2005046710A3 (en) 2005-11-24
EP1680507A2 (de) 2006-07-19
DK1680507T3 (da) 2011-10-10
EP1692159B1 (de) 2010-09-29
ATE513917T1 (de) 2011-07-15
US7485618B2 (en) 2009-02-03
US20110230405A1 (en) 2011-09-22
ATE486087T1 (de) 2010-11-15
ES2375360T3 (es) 2012-02-29
US20130065829A1 (en) 2013-03-14
JP5728329B2 (ja) 2015-06-03
WO2005047314A2 (en) 2005-05-26
US20050238607A1 (en) 2005-10-27
JP2012024091A (ja) 2012-02-09
US20080269139A1 (en) 2008-10-30
US20050203026A1 (en) 2005-09-15
ATE530560T1 (de) 2011-11-15
DE602004029812D1 (de) 2010-12-09
CA2544820A1 (en) 2005-05-26
EP1692160A2 (de) 2006-08-23
US7524816B2 (en) 2009-04-28
JP4843497B2 (ja) 2011-12-21
US20050202535A1 (en) 2005-09-15
EP1692158B1 (de) 2011-10-26
DK1692158T3 (da) 2012-02-06
EP1680507B1 (de) 2011-06-22
WO2005046709A2 (en) 2005-05-26
EP1692160B1 (de) 2010-10-27
WO2005046709A3 (en) 2005-11-24
JP2008500805A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
ECSP044996A (es) Agentes de contraste de objetivo multimérico basado en péptido
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
DE602004011770D1 (de) Fusionsproteine
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
DK1534830T3 (da) In vito-peptid-ekspressionsbibliotek
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
HRP20050024A2 (en) Pegylated t20 polypeptide
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
ATE363531T1 (de) Claudin polypeptide
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften